Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

819 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial.
Lara PN Jr, Tangen C, Heath EI, Gulati S, Stein MN, Meng M, Alva AS, Pal SK, Puzanov I, Clark JI, Choueiri TK, Agarwal N, Uzzo R, Haas NB, Synold TW, Plets M, Vaishampayan UN, Shuch BM, Lerner S, Thompson IM Jr, Ryan CW. Lara PN Jr, et al. Among authors: lerner s. Eur Urol. 2024 Sep;86(3):258-264. doi: 10.1016/j.eururo.2024.05.012. Epub 2024 May 29. Eur Urol. 2024. PMID: 38811313 Clinical Trial.
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide.
Parikh M, Tangen C, Hussain MHA, Gupta S, Callis S, Jo Y, Harzstark A, Paller CJ, George S, Zibelman MR, Cheng HH, Maughan BL, Zhang J, Pachynski RK, Bryce AH, Lin DW, Quinn DI, Lerner SP, Thompson IM, Dorff TB, Lara PN, Agarwal N. Parikh M, et al. Among authors: lerner sp. Eur Urol Oncol. 2024 Oct;7(5):1097-1104. doi: 10.1016/j.euo.2024.03.001. Epub 2024 Mar 23. Eur Urol Oncol. 2024. PMID: 38523017 Free article. Clinical Trial.
Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial.
Pal SK, Grivas P, Gupta S, Dizman N, Zengin Z, Valderrama BP, Rodriguez-Vida A, Roghmann F, Sevillano Fernandez E, Matin SF, Loriot Y, Sridhar SS, Sonpavde G, Fleming MT, Lerner SP, Bellmunt J, Master V, Tripathi A, Davis K, van Veenhuyzen D, Weng R, Daneshmand S. Pal SK, et al. Among authors: lerner sp. Eur Urol. 2024 Apr 4:S0302-2838(24)02247-4. doi: 10.1016/j.eururo.2024.03.023. Online ahead of print. Eur Urol. 2024. PMID: 38580518 No abstract available.
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial.
Gebrael G, Jo Y, Swami U, Plets M, Hage Chehade C, Narang A, Gupta S, Myint ZW, Sayegh N, Tangen CM, Hussain M, Dorff T, Lara PN Jr, Lerner SP, Thompson I, Agarwal N. Gebrael G, et al. Among authors: lerner sp. JAMA Netw Open. 2024 Jul 1;7(7):e2419966. doi: 10.1001/jamanetworkopen.2024.19966. JAMA Netw Open. 2024. PMID: 38980676 Free PMC article. Clinical Trial.
Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial.
Gulati S, Tangen C, Ryan CW, Vaishampayan UN, Shuch BM, Barata PC, Pruthi DK, Bergerot CD, Tripathi A, Lerner SP, Thompson IM Jr, Lara PN Jr, Pal SK. Gulati S, et al. Among authors: lerner sp. JAMA Netw Open. 2024 Aug 1;7(8):e2425288. doi: 10.1001/jamanetworkopen.2024.25288. JAMA Netw Open. 2024. PMID: 39106067 Free PMC article. Clinical Trial.
Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216.
Swami U, Jo Y, Narang A, Plets M, Hage Chehade C, Gebrael G, Gupta S, Myint Z, Tangen C, Lara PN Jr, Thompson IM Jr, Hussain MHA, Dorff TB, Lerner SP, Agarwal N. Swami U, et al. Among authors: lerner sp. Eur Urol Oncol. 2024 Nov 8:S2588-9311(24)00241-4. doi: 10.1016/j.euo.2024.10.013. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39521639
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.
Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F; Bladder Cancer Molecular Taxonomy Group. Kamoun A, et al. Among authors: lerner sp. Eur Urol. 2020 Apr;77(4):420-433. doi: 10.1016/j.eururo.2019.09.006. Epub 2019 Sep 26. Eur Urol. 2020. PMID: 31563503 Free PMC article.
Association Between Antibiotic Prophylaxis Before Cystectomy or Stent Removal and Infection Complications: A Systematic Review.
Antonelli L, Sebro K, Lahmar A, Black PC, Ghodoussipour S, Hamilton-Reeves JM, Shah J, Bente Thoft J, Lerner SP, Llorente C, Lucca I, Preston MA, Psutka SP, Sfakianos JP, Vahr Lauridsen S, Williams SB, Catto J, Djaladat H, Kassouf W, Loftus K, Daneshmand S, Fankhauser CD; Enhanced Recovery After Surgery ERAS Cystectomy Committee. Antonelli L, et al. Among authors: lerner sp. Eur Urol Focus. 2023 Jul;9(4):631-636. doi: 10.1016/j.euf.2023.01.012. Epub 2023 Jan 27. Eur Urol Focus. 2023. PMID: 36710211 Free article. Review.
819 results